January 11th 2025
Through this global alliance, PackGene, Weill Cornell Medicine, and GC4K, an Australian non-profit, intend to deliver a custom-tailored gene therapy solution to treat hereditary spastic paraplegia type 56, a particularly rare neurological disease.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Industry Expert Q&A with David A. Steil
February 22nd 2016Q&A with David A. Steil, pharmaceutical market manager, Camfil Air Pollution ControlPharmTech: Recently there has been an emphasis on green and sustainable technology in the pharmaceutical/biopharmaceutical industries. In what ways does Camfil APC’s technology contribute to sustainability?